Cardiol Therapeutics set to engage in a cozy discussion at Canaccord Genuity's 45th Annual Investment Discussion
Cardiol Therapeutics, a clinical-stage life sciences company, is making significant strides in the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The company's lead small molecule drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.
In a recent development, Cardiol Therapeutics has completed a Phase II trial (ARCHER) investigating CardiolRx™ for acute myocarditis, showing promising results. The trial nearly met its primary endpoint with a near-significant improvement in left ventricular extracellular volume (ECV; p=0.0538), suggesting reduced myocardial inflammation and edema. Significant improvements were observed in other cardiac MRI parameters like reduced left ventricular mass. CardiolRx™ was also found to be safe and well-tolerated in this patient population [1][2][4][5].
For recurrent pericarditis, Cardiol Therapeutics has completed a Phase II MAvERIC-Pilot trial and is currently conducting a Phase III MAVERIC trial, which is ongoing. The company plans to enroll about 50% of patients in the Phase III MAVERIC trial by the second half of 2025 with a completion targeted in the first half of 2026 [1][3]. The MAVERIC Program in recurrent pericarditis comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299).
The US FDA has granted Orphan Drug Designation to CardiolRxTM for the treatment of pericarditis, which includes recurrent pericarditis. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ("US FDA") to conduct clinical studies to evaluate the efficacy and safety of CardiolRxTM in two diseases affecting the heart: recurrent pericarditis and acute myocarditis.
Cardiol is also developing CRD-38, a subcutaneous cannabidiol formulation targeting heart failure, representing an expanding cardiovascular pipeline [1][3].
The replay of a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12, 2025, at 9:30 a.m. EDT will be available for 90 days following the conference. For further information, please contact Trevor Burns at +1-289-910-0855 or [email protected]. The press release was provided by Newsfile via QuoteMedia. For more information about Cardiol Therapeutics, visit their website at cardiolrx.com.
Investors are cautioned not to rely on the forward-looking statements, and such information may not be appropriate for other purposes. Forward-looking information contained in this news release is subject to various risks and uncertainties.
References:
- Cardiol Therapeutics. (n.d.). Cardiol Therapeutics Completes Phase 2 Trial for Acute Myocarditis with CardiolRx™, Showing Promising Results. [online] Available at: https://www.newsfilecorp.com/release/261960
- Cardiol Therapeutics. (n.d.). Cardiol Therapeutics Announces Completion of Phase 2 MAvERIC-Pilot Trial for Recurrent Pericarditis with CardiolRx™ and Initiation of Phase 3 MAVERIC Trial. [online] Available at: https://www.newsfilecorp.com/release/107675
- Cardiol Therapeutics. (n.d.). Cardiol Therapeutics Advancing CardiolRx™ for Recurrent Pericarditis into Phase 3 Clinical Trials. [online] Available at: https://www.globenewswire.com/news-release/2022/01/13/2392520/0/en/Cardiol-Therapeutics-Advancing-CardiolRxTM-for-Recurrent-Pericarditis-into-Phase-3-Clinical-Trials.html
- National Library of Medicine. (n.d.). NCT05180240 - ARCHER: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Safety and Efficacy of CardiolRx™ in Subjects with Acute Myocarditis. [online] Available at: https://clinicaltrials.gov/ct2/show/NCT05180240
- National Library of Medicine. (n.d.). NCT05494788 - MAvERIC-Pilot: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Safety and Efficacy of CardiolRx™ in Subjects with Recurrent Pericarditis. [online] Available at: https://clinicaltrials.gov/ct2/show/NCT05494788
Life science advancements in Cardiol Therapeutics' research have integrated technology, as the company is developing CRD-38, a subcutaneous cannabidiol formulation targeting heart failure, expanding their cardiovascular pipeline. Significant technological progression is also apparent in the pharmaceutical manufacturing of CardiolRx™ oral solution, a lead small molecule drug candidate in clinical development for heart disease treatment.
